Orientador: Francisco Leydson Formiga Feitosa / Banca: Luiz Claudio Nogueira Mendes / Banca: Iveraldo dos Santos Dutra / Banca: Sara Vilar Dantas Simões / Banca: Josir Laine Aparecida Veschi / Resumo: Esse trabalho teve como objetivo avaliar, em um rebanho com presença de animais com sinais clínicos da enfermidade, a aplicabilidade e eficácia das medidas de controle para a atrite-encefalite caprina e perdas produtivas associadas. Os animais foram testados sorologicamente e algumas medidas de controle foram instituídas, entre elas: segregação dos rebanhos (positivo e negativo), retirada dos cabritos ao nascimento, aleitamento dos neonatos com colostro/leite de vaca ou de cabra tratados termicamente, linha de ordenha e manejo reprodutivo de acordo com status sorológico e descarte orientado de animais reagentes. Dados produtivos tais quais produção de leite, taxa de prenhez, peso dos animais adultos e crias, taxa de morbidade, mortalidade e descarte foram avaliados. Os custos relacionados à implantação do programa e perdas associadas à produtividade também foram analisados. A soroprevalência da doença decresceu a partir da segunda sorologia, atingindo a menor taxa na quarta sorologia (40,54%) e voltando a aumentar no final do estudo (50,72%). Animais soropositivos e com duas lactações produziram 0,26 litros a menos de leite diariamente quando comparados aos animais soronegativos. O peso das crias ao nascimento também foi menor em animais que provinham de mães sororeagentes. Conclui-se que as medidas de controle são aplicáveis em rebanhos comerciais, entretanto possuem sérias implicações quanto a sua eficácia em rebanhos com soroprevalência intermediária e alta, contribuindo p... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: The objective of this study was to evaluate the application and efficacy of control measures for caprine arthritis encephalitis and associated productive losses in a herd with the presence of animals with clinical signs of the disease. The animals were tested serologically and some control measures were instituted, including: segregation of herds (positive and negative), removal of goats at birth, suckling of newborns with colostrum / cow's milk or thermally treated goat's milk, management line and reproductive management according to serological status and discarded oriented of reactive animals. Productive data such pregnancy rate, adult and calf weight, mortality rate, mortality and discards. Costs related to program implementation and losses associated with productivity were also analyzed. The seroprevalence of the disease decreased after the second serology, with a lower rate in the fourth serology (40.54%) and increasing again at the end of the study (50.72%). Seropositive animals with two lactations produced 0.26 liters less milk daily when compared to seronegative animals. The weight of the offspring at birth was also lower in animals that came from mothers who were seroreagentes. It is concluded that control measures are approached, such as their efficacy in herds with intermediate and high seroprevalence, contributing little to a reduction of new cases. The productive impact was mainly reflected in milk production and in the cost to implement the high-level control p... (Complete abstract click electronic access below) / Doutor

Os vetores retrovirais representam uma das melhores opções para transferência e terapia gênica, pois fornecem expressão do transgene em longo prazo. Entretanto, a inserção do provírus pode causar mutagênese insercional, induzindo proto-oncogenes. Eventos deste tipo têm sido descritos em protocolos clínicos para o tratamento de SCID-X1, doença granulomatosa crônica e talessemia beta, quando vetores retrovirais (oncorretrovirus) foram utilizados. Atualmente, existem poucos métodos simples e rápidos para revelar e quantificar a expansão clonal. Assim, descrevemos a construção uma biblioteca de vetores contendo uma marcação aleatória, denominada código de barras. O sequenciamento do código de barras permitirá revelar, caracterizar e até quantificar a expansão clonal de uma população de células transduzidas. Esta metodologia ajudará a testar novos arranjos de promotores e genes terapêuticos, para o desenvolvimento de vetores mais seguros contribuindo para a redução da probabilidade de um evento de proliferação clonal desencadeado pela mutagênese insercional. / Retroviral vectors represent one of the best options for gene transfer and therapy, where long-term transgene expression is required. However, insertion of the provirus can cause insertional mutagenesis, which may have adverse consequences, such as induction of proto-oncogenes. Such events have been described in clinical trials for the treatment of SCID-X1, chronic granulomatous disease and beta thalessemia with some retroviral vectors. Currently, there are few simple and quick methods that can reveal and quantify clonal expansion. Thus, we describe the construction of a vector library containing random markers, called \"barcodes\". The sequencing of the barcode could reveal, characterize and quantify the clonal expansion of a transduced cells population. This methodology will be valuable to test new arrangements of promoters and therapeutic genes, allowing the development of safer vectors, helping to reduce the probability of clonal proliferation events triggered by insertional mutagenesis.

Arteriosklerose führt zu schwerwiegenden klinischen Komplikationen bei Herz-Kreislauf-erkrankungen, welche die führenden Todesursachen in den westlichen Industrieländern sind. Die Arteriosklerose ist typischerweise eine Erkrankung arterieller Gefäße und betrifft nicht die venöse Gefäßwand. Bei der Entstehung von Arteriosklerose spielen die Endothelzellen als Barrierezellen und Regulatoren der Gefäßfunktion eine Schlüsselrolle. Ein wichtiger Schwerpunkt der Forschung ist die Differenzierung der Endothelzellen. Arterielle und venöse Endothelzellen weisen schon im frühen Embryonalstadium unterschiedliche Phänotypen auf. Ein besseres Verständnis der arterio-venösen Differenzierung wäre von großer Bedeutung für antiarteriosklerotische Therapien. Darüber hinaus könnte eine Reprogrammierung (z.B. von Vene in Arterie) entscheidend für neue Therapieansätze bei der Senkung der Restenoserate venöser Bypässe von Patienten mit koronarer Herzkrankheit und bei AV-Shunt-Operationen von dialysepflichtigen Patienten sein. In dieser Arbeit wurden differenzierte humane primäre arterielle und venöse Endothelzellen nach Genmodulation untersucht. Der Fokus der Genmodulation wurde auf das arterielle Markergen Hey2 und auf das venöse Markergen COUP-TFII gelegt. Das arterielle Markergen Hey2 ist ein Zielgen der Notch-Signalkaskade, während der molekulare Mechanismus der Rolle von COUP-TFII bei der venösen Differenzierung noch nicht bekannt ist. Daher wurde der Einfluss des arteriellen Markergens Hey2 und des venösen Markergens COUP-TFII auf die Notch-Signalkaskade untersucht, um ein besseres Verständnis über die molekularen Mechanismen der arterio-venösen Differenzierung zu gewinnen. Da humane primäre Endothelzellen mit kommerziell verfügbaren Transfektionsmitteln schwer transfizierbar sind, wurde zunächst ein lentivirales Vektorsystem etabliert. Hiermit wurde eine erfolgreiche und stabile Genexpression bzw. Genrepression in arteriellen und venösen Endothelzellen ermöglicht. Die Genmodulationen in arteriellen Endothelzellen, die durch die Expression des venösen Markergen COUP-TFII bzw. durch die Repression des arterellen Markergen Hey2 verursacht wurden, führten zu der neuen Erkenntnis, dass das venöse Markergen COUP-TFII in arteriellen Endothelzellen als ein Repressor des arteriellen Markergens Hey2 fungiert. Diese Repression wird durch eine direkte Bindung von COUP-TFII an den Hey2-Promotor vermittelt. Die COUP-TFII Expression bewirkte keine Veränderung in der Expression von Notch4, Dll4 und Nrp1. Dies könnte bedeuten, dass (i) COUP-TFII in arteriellen Endothelzellen kein Regulator von diesen Genen ist, (ii) Kooperationspartner von COUP-TFII fehlen, die in arteriellen Endothelzellen nicht vorhanden sind, oder (iii) der molekulare Mechanismus dieser Gene aufgrund seiner wichtigen Rolle nicht durch die Modifikation eines einzigen Gens beeinflussbar ist, da die Gene der Notch-Signalkaskade redundant kontrolliert werden. In venösen Endothelzellen wurden Genmodulationen durch Expression des arteriellen Markergens Hey2 bzw. durch die Repression des venösen Markergens COUP-TFII durchgeführt. Eine Expression des arteriellen Markergens Hey2 in venösen Endothelzellen konnte nicht die Expression der Gene der Notch-Signalkaskade aktivieren. Dies bedeutet, dass die Regulation dieser Gene durch einen übergeordneten molekularen Mechanismus gesichert ist. Interessanterweise konnte die Expression von Hey2 eine Reduktion der Hey1 Expression bewirken. Dies ist ein alternativer Effekt von Hey2 im Vergleich zu arteriellen Endothelzellen. Eine Repression des venösen Markergens COUP-TFII konnte die Expression der Gene Dll4, EphrinB2 und EphB4 induzieren. Vermutlich ist die Induktion der EphB4 Expression ein Kompensationsmechanismus auf die reduzierte COUP-TFII Expression. COUP-TFII sichert den venösen Phänotyp wahrscheinlich durch die Repression von EphrinB2 und Dll4, wobei die Reduktion von Dll4 vermutlich eine größere Bedeutung hat. Da Dll4 ein Ligand und Aktivator der Notch-Signalkaskade ist, ist seine Repression entscheidend für venöse Endothelzellen. Das arterielle Markergen Hey2 ist für die normale Embryogenese von großer Bedeutung, jedoch ist Hey2 als eines der Zielgene der Notch-Signalkaskade wahrscheinlich nicht in der Lage, molekulare Mechanismen, die zu unterschiedlichen endothelialen Phänotypen führen, zu aktivieren. Um arterielle Endothelzellen zu einem Reprogramming zu bewegen, wären wahrscheinlich Genmodulationen der Mitglieder der Notch-Signalkaskade, die upstream von Hey2 liegen, nötig. Hingegen ist die Rolle des venösen Markergens COUP-TFII in der Regulation der arterio-venösen Differenzierung von entscheidender Bedeutung. COUP-TFII spielt eine direkte Rolle in der Aufrechterhaltung der venösen Identität. Die Repression von COUP-TFII in venösen Endothelzellen bewirkt, dass sich die Expression des Gens Dll4, das die Notch-Signalkaskade aktiviert, in Richtung des arteriellen Expressionsniveaus bewegt. Für eine Reprogrammierung der venösen Endothelzellen in einen arteriellen Phänotyp ist das venöse Markergen COUP-TFII eines der Zielgene.

El objetivo del presente estudio fue determinar la seroprevalencia del virus de la artritis- encefalitis viral caprina (AEVC) en cabras de cuatro provincias del departamento de Lima. Con este fin se colectaron 754 muestras de suero de cabras mayores a 12 meses de edad entre hembras (n=698) y machos (n=56) de 89 diferentes rebaños criados en forma estabulada (n=3), semi-extensiva (n=40) y transhumante (n=46) para la detección de anticuerpos contra el AEVC mediante la prueba de ELISA de competición. El 1.3±0.8 % (10/754) de las cabras tuvieron anticuerpos contra el AEVC. Los 10 seropositivos fueron hembras de 2 a 5 años de edad clínicamente normal perteneciente a un solo rebaño de 103 animales de crianza semi-extensiva del distrito de Huaral, provincia de Huaral representando 9.7% (10/103) de seropositividad dentro del rebaño. Todos los reproductores machos resultaron seronegativos. Se concluye que la artritis encefalitis viral caprina está presente en baja prevalencia en rebaños caprinos de crianza semi-extensiva estudiados.

<p>The pathogenesis of osteoarthritis is mediated in part by inflammatory cytokines including interleukin-1 (IL-1), which promote degradation of articular cartilage and prevent human mesenchymal stem cell (hMSC) chondrogenesis. We combined gene therapy and functional tissue engineering to develop engineered cartilage with immunomodulatory properties that allow chondrogenesis in the presence of pathologic levels of IL-1 by inducing overexpression of IL-1 receptor antagonist (IL-1Ra) in hMSCs via scaffold-mediated lentiviral gene delivery. A doxycycline-inducible vector was used to transduce hMSCs in monolayer or within 3D woven PCL scaffolds to enable tunable IL-1Ra production. In the presence of IL-1, IL-1Ra-expressing engineered cartilage produced cartilage-specific extracellular matrix, while resisting IL-1-induced upregulation of matrix metalloproteinases and maintaining mechanical properties similar to native articular cartilage. The ability of functional engineered cartilage to deliver tunable anti-inflammatory cytokines to the joint may enhance the long-term success of therapies for cartilage injuries or osteoarthritis.</p><p> Following this, we modified this anti-inflammatory engineered cartilage to incorporate rabbit MSCs and evaluated this therapeutic strategy in a pilot study in vivo in rabbit osteochondral defects. Rabbits were fed a custom doxycycline diet to induce gene expression in engineered cartilage implanted in the joint. Serum and synovial fluid were collected and the levels of doxycycline and inflammatory mediators were measured. Rabbits were euthanized 3 weeks following surgery and tissues were harvested for analysis. We found that doxycycline levels in serum and synovial fluid were too low to induce strong overexpression of hIL-1Ra in the joint and hIL-1Ra was undetectable in synovial fluid via ELISA. Although hIL-1Ra expression in the first few days local to the site of injury may have had a beneficial effect, overall a higher doxycycline dose and more readily transduced cell population would improve application of this therapy. </p><p> In addition to the 3D woven PCL scaffold, cartilage-derived matrix scaffolds have recently emerged as a promising option for cartilage tissue engineering. Spatially-defined, biomaterial-mediated lentiviral gene delivery of tunable and inducible morphogenetic transgenes may enable guided differentiation of hMSCs into both cartilage and bone within CDM scaffolds, enhancing the ability of the CDM scaffold to provide chondrogenic cues to hMSCs. In addition to controlled production of anti-inflammatory proteins within the joint, in situ production of chondro- and osteo-inductive factors within tissue-engineered cartilage, bone, or osteochondral tissue may be highly advantageous as it could eliminate the need for extensive in vitro differentiation involving supplementation of culture media with exogenous growth factors. To this end, we have utilized controlled overexpression of transforming growth factor-beta 3 (TGF-β3), bone morphogenetic protein-2 (BMP-2) or a combination of both factors, to induce chondrogenesis, osteogenesis, or both, within CDM hemispheres. We found that TGF-β3 overexpression led to robust chondrogenesis in vitro and BMP-2 overexpression led to mineralization but not accumulation of type I collagen. We also showed the development of a single osteochondral construct by combining tissues overexpressing BMP-2 (hemisphere insert) and TGF-β3 (hollow hemisphere shell) and culturing them together in the same media. Chondrogenic ECM was localized in the TGF-β3-expressing portion and osteogenic ECM was localized in the BMP-2-expressing region. Tissue also formed in the interface between the two pieces, integrating them into a single construct. </p><p> Since CDM scaffolds can be enzymatically degraded just like native cartilage, we hypothesized that IL-1 may have an even larger influence on CDM than PCL tissue-engineered constructs. Additionally, anti-inflammatory engineered cartilage implanted in vivo will likely affect cartilage and the underlying bone. There is some evidence that osteogenesis may be enhanced by IL-1 treatment rather than inhibited. To investigate the effects of an inflammatory environment on osteogenesis and chondrogenesis within CDM hemispheres, we evaluated the ability of IL-1Ra-expressing or control constructs to undergo chondrogenesis and osteogenesis in the prescence of IL-1. We found that IL-1 prevented chondrogenesis in CDM hemispheres but did not did not produce discernable effects on osteogenesis in CDM hemispheres. IL-1Ra-expressing CDM hemispheres produced robust cartilage-like ECM and did not upregulate inflammatory mediators during chondrogenic culture in the presence of IL-1.</p> / Dissertation

Les IFN-I (interférons de type I), principalement IFN et , constituent un mécanisme de défense primordial de l’hôte contre les pathogènes. Pourtant, dans le cas du VIH-1 (virus de l’immunodéficience humaine), la relation entre les IFN-I et la réplication virale apparaît plus complexe. En effet, si les IFN-I inhibent la réplication du VIH-1 ex vivo, un état d’hyperactivation permanent de la réponse IFN-I a été récemment associé à la progression vers le SIDA ainsi qu’à une forte virémie chez les patients infectés par le VIH-1. De même, la dérégulation de la réponse IFN-I est un critère déterminant dans l’issue pathogénique de certains modèles d’infection virale chez le singe. Si l’hypothèse du rôle pathogénique des IFN-I s’avère correcte, le VIH-1 pourrait avoir évolué afin de se répliquer même en présence d’une telle réponse, qui semble être au final, plus délétère pour l’hôte que pour le virus. L’objectif de ce travail a été d’évaluer la résistance du VIH-1 aux IFN. Dans ce contexte, le VIH-1 a été comparé au VIH-2 et au SIVmac (virus de l’immunodéficience simienne), virus phylogénétiquement proches mais peu ou pas pathogènes pour l’homme, lors de l’infection de plusieurs types cellulaires tels que des lymphocytes, des macrophages et des cellules dendritiques. En accord avec l’hypothèse initiale de travail, les expériences réalisées ont montré que le VIH-1 est capable de se répliquer dans les cellules primaires prétraitées avec des doses d’IFN comparables à celles mesurées in vivo, alors que la réplication des virus VIH-2/SIVmac est complètement bloquée, même à des concentrations très faibles d’IFN. Ce travail a permis de démontrer que le blocage induit par l’IFN s’exerce au niveau des phases précoces de l’infection et plus précisément à l’étape de la transcription inverse. En effet, les données obtenues suggèrent que l’IFN induit l’expression d’un effecteur cellulaire qui affecte différentiellement la stabilité des complexes viraux, ce qui se traduit par un défaut d’accumulation de l’ADN viral plus important pour le VIH-2 et le SIVmac, que pour le VIH-1. La différence de susceptibilité des lentivirus de primates aux IFN-I pourrait ainsi expliquer en partie, les différents niveaux de réplication de ces virus, associés à leurs degrés de pathogénicité in vivo. / Type I Interferons (IFN-α/β, herein IFNs) provide an important mechanism of defense against pathogens and regulate in a paracrine and autocrine manner both intrinsic and adaptive immune responses. In the case of HIV-1 however, the relationship between IFNs and viral replication appears more complex. Indeed, if IFNs have been described to interfere with HIV-1 at basically all phases of its life cycle ex vivo, an IFN-induced state is linked to AIDS progression and to high viral loads in HIV-1 infected individuals. Similarly, a deregulated and prolonged IFN production/state seems one of the main distinguishing features between pathogenic and non-pathogenic SIV infection in primate animal models, suggesting that a deregulated IFN-state may be more detrimental to the host than to the virus itself in vivo.If this hypothesis is correct and if HIV-1 plays an active role in the perpetration of this antiviral state, it is possible that HIV-1 may have overall evolved to cope with this environment, remaining able to replicate despite it.To determine whether HIV-1 was better armed to replicate in the presence of an IFN-state environment than other primate lentiviruses, we compared HIV-1 to SIVmac and more importantly to HIV-2 that albeit capable of inducing AIDS in humans does so in a much less aggressive manner. In agreement with the initial hypothesis, our results indicate that HIV-1 is better fit to replicate in primary cells in the presence of amounts of IFN comparable to the ones measured in vivo, while the replication of HIV-2/SIVmac viruses is completely blocked even in the presence of low levels of IFN. By decorticating the effects of IFNs on the early and late phases of the viral life cycle in primary macrophages, we show here that the main target of the differential action of IFNs are the early phases of infection. More specifically, with time kinetics that we determine herein, IFNs induce cellular factor/s that differentially affect the stability of pre-reverse transcription complexes of HIV-2, but not of HIV-1. Our results could underlie a different evolutionary adaptation of primate lentiviruses to interferons that might be responsible for their different pathogenicity in vivo.

Estudou-se a freqüência da ocorrência de anticorpos antivírus da Artrite-encefalite dos Caprinos, em caprinos de 14 plantéis localizados no Estado de São Paulo, por um período de 2 anos, utilizando-se a técnica de imunodifusão em gel de ágar. A prevalência obtida foi de 26,3%, sendo significativamente maior nos caprinos mantidos em regime intensivo (31,8% - 733/2303) de criação do que no sistema semi-extensivo (13,1% - 128- 977). A infecção pelo vírus da Artrite-encefalite dos Caprinos aumentou gradativa e significativamente após os 6 meses de idade, havendo predominância da infecção nos caprinos mais velhos. Não se detectou influência de fatores sexuais sobre a prevalência da enfermidade determinada em caprinos do sexo feminino (27,9% - 663/2375) e masculino (32,3% - 94/291). A prevalência da doença foi significativamente maior nos caprinos das raças Anglo Nubiana (63,8% - 88/138) e Toggenbourg (56,0% - 28/50) do que nas demais raças estudadas: Saanen (27,4% - 673/2458), Alpina (11,9% - 59/497), Bôer (5,9% - 2/34) e caprinos mestiços (10,7% - 11/103). Paralelamente realizou-se estudo clínico dos animais infectados pelo vírus da Artrite-encefalite dos Caprinos, quando pudemos demonstrar que 17,1% (64/374) dos caprinos sororeagentes apresentavam a forma clínica articular da enfermidade e que 6,6% (17/249) das cabras sororeagentes apresentavam a forma mamária. A possibilidade de transmissão vertical transplacentária foi menor do que 3,8%. Verificou-se ser pequena a possibilidade dos cabritos se infectarem pelo colostro de cabras sororeagentes positivas, mas podem se infectar pelo leite oriundos dessas cabras infectadas (18,8% - 3/16). O tempo de duração dos anticorpos séricos adquiridos passivamente pelo colostro variou de 60 a 120 dias. Demonstrou-se, indiretamente, a presença e a viabilidade do vírus no sangue circulante, colostro e leite de caprinos infectados, bem como a possibilidadede infectar animais susceptíveis por inoculação, sendo o período de incubação de 45 a 60 dias. Não se demonstrou diferenças significativas dos teores séricos de proteína total, gamaglobulina e da atividade enzimática da glutamiltransferase - &gamma;GT em cabritos que receberam colostro de cabras infectadas ou não infectadas pelo mencionado vírus. / The frequency of occurrence of antibodies anti-caprine arthritis-encephalitis virus was studied in 14 herds in the State of São Paulo, during 2 years, using agar gel immunodiffusion. Prevalence was equal to 26.3%, and was significantly higher in animals kept under an intensive management scheme (31.8% - 733/2303), than in animals kept under a semi-extensive one (13.1% - 128- 977). Infection by the caprine arthritis-encephalitis virus increased gradual and significantly after 6 months of age. Infection was predominant in older animals. There was no gender influence on the prevalence of the disease, both in females (27.9% - 663/2375) and males (32.3% - 94/291). In relation to breed, prevalence of the disease was significantly higher in Anglo-Nubian (63.8% - 88/138) and Toggenbourg animals (56.0% - 28/50), than in the rest of the breeds studied: Saanen (27.4% - 673/2458), Alpine (11.9% - 59/497), Boer (5.9% - 2/34) and mixed breed animals (10.7% - 11/103). A clinical study of the animals infected by caprine arthritis-encephalitis virus was also performed. It was observed that 17.1% (64/374) of seroreagents presented the articular form of the disease and that 6.6% (17/249) of the seroreagent females presented the mammary form of the disease. The possibility of vertical, transplacentary transmission was lower than 3.8%. It was observed that the probability of infection of kids by colostrum of infected females was low (18.8% - 3/16). Antibodies passively acquired by colostrum ingestion lasted from 60 to 120 days. The presence and viability of the virus circulating in blood, colostrum and milk of infected animals, as well as the possibility of infection of susceptible animals by inoculation was indirectly demonstrated. Incubation period ranged from 45 to 60 days. There was no significant difference in serum levels of total protein and gammaglobulin, and in enzymatic activity of glutamiltransferase - &gamma;GT in kids that received colostrum from infected and non-infected females.

SerpinB2 (aka plasminogen activator type 2) is well described as an extracellular inhibitor of urokinase-type plasminogen activator (uPA). However, the majority of SerpinB2 is retained intracellularly, and many uPA-independent activities have been reported for SerpinB2 suggesting an alternate function. This thesis explores the role of SerpinB2 in epithelial tumour cell lines, highlights the problems associated with various expression systems and argues that SerpinB2 has no role in growth or apoptosis of tumour cells. A potential role for immune modulation and angiogenesis is suggested in in vivo models. Previous research using SerpinB2 transfected, clonally selected tumour cell lines suggested that SerpinB2 regulates the retinoblastoma tumour suppressor protein (Rb) by binding and protecting Rb from degradation. Despite the use of two techniques under numerous conditions and positive controls, no significant interaction between SerpinB2 and Rb was found. SerpinB2 was reported to bind Rb through a PENF homology motif located within the SerpinB2 C-D interhelical loop region. The PENF homology motif was postulated to represent the motif responsible for binding to the C-pocket of Rb. Epstein Barr Virus nuclear antigen 6 (EBNA6) is a known Rb binding protein, which contains two predicted PENF homology motifs. However, mutation of the two PENF homology motifs within EBNA6 did not reduce Rb binding. Furthermore, the SerpinB2 PENF homology motif is actually not well conserved between SerpinB2 proteins from multiple species, whereas other regions of the SerpinB2 C-D loop show a high level of conservation. These data do not support a role for SerpinB2 and the PENF homology motif in Rb binding. SerpinB2 has been proposed to have a role in regulating growth and apoptosis. To further investigate this proposed phenotype of SerpinB2, SerpinB2 was expressed in a range of epithelial tumour lines using transient transfection. No change in growth, apoptosis or Rb levels were found. After ≈2-3 month antibiotic selection for the SerpinB2-expressing plasmid, SerpinB2 protein was lost without the loss of the transgene, indicating selective pressure against long-term SerpinB2 protein expression. To further investigate long-term SerpinB2 expression adenovirus and lentivirus vectors were used. Infection of tumour cell lines with adenovirus vectors expressing SerpinB2 resulted in reduced cell growth, characterised by increased p53 (but not Rb) levels and G2 arrest or apoptosis. When SerpinB2 expressing lentivirus vectors were used to transduce the same tumour cell lines, high levels of long-term expression of functional SerpinB2 was achieved. However, SerpinB2-expressing cell lines showed no differences in growth, proliferation, Rb levels, or apoptosis induced by a range of agents. Growth and apoptosis observed with adenovirus SerpinB2 had all the characteristics of adenovirus-associated toxicity, which has been reported previously for specific proteins. These experiments highlighted the problems associated with SerpinB2 expression systems and suggest that SerpinB2 expression per se is not toxic nor has a role in regulating Rb, growth and apoptosis. Screening of a number of tumour cell lines identified the HPV16 transformed cervical cancer line as expressing high levels of SerpinB2. SerpinB2 was located both extracellularly and intracellularly with a cytoplasmic and nuclear distribution. A high molecular weight SerpinB2 species was identified in CaSki cells and was shown to be the N-linked glycosylated species. Sequencing showed the protein to be Type A SerpinB2 and the protein was shown to form an inhibitory complex with uPA. An abundant low molecular weight SerpinB2 species was also identified in CaSki cell supernatants and appeared to be a proteolytic fragment of SerpinB2. Treatment of CaSki with PMA, TNFα and IFNγ increased SerpinB2 levels. Lentiviral based shRNA failed to significantly down regulate SerpinB2 expression and increasing SerpinB2 levels with lentiviral expression did not change growth, apoptosis, Rb levels or E7 transcription. Lentiviral expression of SerpinB2 in (normally SerpinB2 negative) HPV16 transformed SiHa cells, also failed to show changes in Rb levels or E7 transcription. CaSki thus express wild-type and functional SerpinB2, but no evidence could found that SerpinB2 effects HPV16 E7 transcription or Rb levels. The data presented identifies CaSki as valuable source of biologically functional SerpinB2. SerpinB2 expression in breast cancer cells has been associated with positive prognosis. Tubo, a SerpinB2-negative murine breast carcinoma cell line, was transduced with lentivirus expressing SerpinB2 and grown subcutaneously in BALB/c mice. SerpinB2 expressing tumours appeared red and were larger than control tumours. Furthermore, SerpinB2 expressing tumours had a ≈2 fold higher density of blood vessels when compared to Tubo and Tubo expressing EGFP. Mice carrying tumours expressing SerpinB2 also showed reduced anti-tumour IgG2 responses. These data suggest that a role for SerpinB2 in regulating angiogenesis and antitumour immunity. In conclusion, this thesis challenges the notion that SerpinB2 regulates Rb, cell cycle, and apoptosis and suggests a potential role for SerpinB2 in tumour angiogenesis and immunity.

SerpinB2 (aka plasminogen activator type 2) is well described as an extracellular inhibitor of urokinase-type plasminogen activator (uPA). However, the majority of SerpinB2 is retained intracellularly, and many uPA-independent activities have been reported for SerpinB2 suggesting an alternate function. This thesis explores the role of SerpinB2 in epithelial tumour cell lines, highlights the problems associated with various expression systems and argues that SerpinB2 has no role in growth or apoptosis of tumour cells. A potential role for immune modulation and angiogenesis is suggested in in vivo models. Previous research using SerpinB2 transfected, clonally selected tumour cell lines suggested that SerpinB2 regulates the retinoblastoma tumour suppressor protein (Rb) by binding and protecting Rb from degradation. Despite the use of two techniques under numerous conditions and positive controls, no significant interaction between SerpinB2 and Rb was found. SerpinB2 was reported to bind Rb through a PENF homology motif located within the SerpinB2 C-D interhelical loop region. The PENF homology motif was postulated to represent the motif responsible for binding to the C-pocket of Rb. Epstein Barr Virus nuclear antigen 6 (EBNA6) is a known Rb binding protein, which contains two predicted PENF homology motifs. However, mutation of the two PENF homology motifs within EBNA6 did not reduce Rb binding. Furthermore, the SerpinB2 PENF homology motif is actually not well conserved between SerpinB2 proteins from multiple species, whereas other regions of the SerpinB2 C-D loop show a high level of conservation. These data do not support a role for SerpinB2 and the PENF homology motif in Rb binding. SerpinB2 has been proposed to have a role in regulating growth and apoptosis. To further investigate this proposed phenotype of SerpinB2, SerpinB2 was expressed in a range of epithelial tumour lines using transient transfection. No change in growth, apoptosis or Rb levels were found. After ≈2-3 month antibiotic selection for the SerpinB2-expressing plasmid, SerpinB2 protein was lost without the loss of the transgene, indicating selective pressure against long-term SerpinB2 protein expression. To further investigate long-term SerpinB2 expression adenovirus and lentivirus vectors were used. Infection of tumour cell lines with adenovirus vectors expressing SerpinB2 resulted in reduced cell growth, characterised by increased p53 (but not Rb) levels and G2 arrest or apoptosis. When SerpinB2 expressing lentivirus vectors were used to transduce the same tumour cell lines, high levels of long-term expression of functional SerpinB2 was achieved. However, SerpinB2-expressing cell lines showed no differences in growth, proliferation, Rb levels, or apoptosis induced by a range of agents. Growth and apoptosis observed with adenovirus SerpinB2 had all the characteristics of adenovirus-associated toxicity, which has been reported previously for specific proteins. These experiments highlighted the problems associated with SerpinB2 expression systems and suggest that SerpinB2 expression per se is not toxic nor has a role in regulating Rb, growth and apoptosis. Screening of a number of tumour cell lines identified the HPV16 transformed cervical cancer line as expressing high levels of SerpinB2. SerpinB2 was located both extracellularly and intracellularly with a cytoplasmic and nuclear distribution. A high molecular weight SerpinB2 species was identified in CaSki cells and was shown to be the N-linked glycosylated species. Sequencing showed the protein to be Type A SerpinB2 and the protein was shown to form an inhibitory complex with uPA. An abundant low molecular weight SerpinB2 species was also identified in CaSki cell supernatants and appeared to be a proteolytic fragment of SerpinB2. Treatment of CaSki with PMA, TNFα and IFNγ increased SerpinB2 levels. Lentiviral based shRNA failed to significantly down regulate SerpinB2 expression and increasing SerpinB2 levels with lentiviral expression did not change growth, apoptosis, Rb levels or E7 transcription. Lentiviral expression of SerpinB2 in (normally SerpinB2 negative) HPV16 transformed SiHa cells, also failed to show changes in Rb levels or E7 transcription. CaSki thus express wild-type and functional SerpinB2, but no evidence could found that SerpinB2 effects HPV16 E7 transcription or Rb levels. The data presented identifies CaSki as valuable source of biologically functional SerpinB2. SerpinB2 expression in breast cancer cells has been associated with positive prognosis. Tubo, a SerpinB2-negative murine breast carcinoma cell line, was transduced with lentivirus expressing SerpinB2 and grown subcutaneously in BALB/c mice. SerpinB2 expressing tumours appeared red and were larger than control tumours. Furthermore, SerpinB2 expressing tumours had a ≈2 fold higher density of blood vessels when compared to Tubo and Tubo expressing EGFP. Mice carrying tumours expressing SerpinB2 also showed reduced anti-tumour IgG2 responses. These data suggest that a role for SerpinB2 in regulating angiogenesis and antitumour immunity. In conclusion, this thesis challenges the notion that SerpinB2 regulates Rb, cell cycle, and apoptosis and suggests a potential role for SerpinB2 in tumour angiogenesis and immunity.

Le virus de l'immunodéficience bovine (VIB) est un rétrovirus qui partage des propriétés similaires avec les autres lentivirus, dont le virus de l'immunodéficience humaine (VIH). L'expression des gènes lentiviraux dépend des protéines régulatrices virales Tat et Rev qui interviennent, dans le cycle de réplication virale, aux niveaux transcriptionnel et post-transcriptionnel, respectivement. Les longues répétitions terminales (LTR) du génome viral fournissent, quant à elles, les signaux d'initiation, d'amplification et de terminaison de la transcription. La protéine Tat, pour exercer son activité transactivatrice, interagit avec une séquence d'ARN appelée TAR ("transactivaton response element") présente sur tous les transcrits viraux. Tat recrute le facteur positif de l'élongation de la transcription b (pTEFb) au niveau du promoteur viral des LTR pour augmenter l'efficacité de transcription de l'ARN polymérase II. La protéine nucléaire Rev est impliquée dans le transport nucléo-cytoplasmique des ARN viraux mono- et non épissés. Récemment, une protéine hybride Tat/Rev constituée de 236 acides aminés (Tat 236) a été découverte à partir de virions isolés de la rate de lapins qui avaient été infectés trois ans auparavant, suggérant une évolution temporelle du virus in vivo. L'objectif de ce travail était de déterminer si des variations génétiques et/ou fonctionnelles pouvaient se retrouver dans d'autres parties du génome du variant du VIB impliquées dans la régulation de l'expression génique virale, notamment au niveau du LTR et du gène accessoire rev du VIB. Ainsi, en utilisant la technique d'amplification en chaîne des gènes (PCR), une séquence LTR mutante (LTRm) fut mise en évidence, démontrant la présence de trois mutations aux positions 191, 250 et 271 lorsque comparée à celle du LTR pré-infection obtenue du génome des virus ayant servi à l'infection des lapins. La séquence du LTR pré-infection était 100% identique à celle du LTR sauvage (LTRs) retrouvée dans la littérature. En utilisant un test de transactivation CAT in vitro avec la protéine Tat103 comme agent transactivateur, le LTRm démontra une activité promotrice d'au moins deux fois supérieure à celle obtenue avec le LTRs. Pour tenter d'associer ces mutations au nouveau caractère phénotypique de LTRm, des mutants de restauration furent développés par PCR-mutagenèse pour revenir au phénotype LTRs. L'ensemble des résultats obtenus suggère que les mutations en positions 250 et 271 seraient impliquées dans l'activité promotrice augmentée de LTRm. Finalement, l'analyse de séquences du gène rev pré- et post- infection a montré deux mutations aux positions 48 (Val → Ile) et 76 (Pro → Leu), la dernière étant localisée dans un domaine riche en arginine. Fait intéressant, la mutation à la position 76 avait aussi été rapportée auparavant dans la portion Rev de Tat236. Les résultats obtenus suggèrent une évolution temporelle du VIB dans le cours d'infections in vivo au niveau du LTR et du gène rev, similaire à celle antérieurement décrite pour le gène tat. ______________________________________________________________________________ MOTS-CLÉS DE L’AUTEUR : lentivirus, région du LTR, gène rev, diversité génétique